G7 Freedom Constrained Vivacit-E Liners
← catalyst calendarNCT05587244 · readout ≤ 4,152 d
Sponsored by Zimmer Biomet (industry) · ZBH — their whole pipeline →.
Phase
Not applicable
Status
Enrolling by invitation
Study type
Interventional
Design
Na · None · Treatment
Enrollment
202estimated
Sites
10
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-05-08 | actual | When the study began enrolling |
| Primary completion | Dec 2037 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2038 | estimated | The whole study's end, after follow-up |
| First posted | 2022-10-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Osteoarthritis, Hip
- Rheumatoid Arthritis
- Non-Union Fracture
- Trochanteric Fractures
- Femoral Neck Fractures
- Avascular Necrosis
- Dislocation, Hip
Intervention
- Device: Total Hip Arthroplasty with G7 Freedom Constrained Vivacit-E Liners
Primary outcome
what the primary-completion date above is the date OFSurvival of the study device
measured 10 years
Permalink · ZBH's whole pipeline · Catalyst calendar · Every registered study · What changed